A combination phase I study of weekly paclitaxel and doxifluridine in advanced gastric cancer patients

Anticancer Research

Volumn 25, Issue 2 B, 2005, Pages 1291-1296

  Takeyoshi, Izumi ^a,f   Makita, Fujio ^b   Tanahashi, Yoshifumi ^c   Yokomori, Tadahiro ^d   Iwazaki, Shigeru ^e   Kawashima, Yoshiyuki ^a   Iwanami, Kotaro ^a   Yamada, Tatsuya ^a   Kawate, Susumu ^a   Hamada, Kunihiro ^a   Sunose, Yutaka ^a   Yoshida, Miho ^a   Horiguchi, Jun ^a   Iesato, Hiroshi ^d   Kobayashi, Mitsunobu ^a   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Shibukawa Medical Center   (Japan)

^c Shibukawa General Hospital   (Japan)

^d Ojiya General Hospital   (Japan)

^e Tatebayashi Kosei Hospital   (Japan)

^f GUNMA UNIVERSITY   (Japan)

Author keywords

Doxifluridine; Gastric cancer; Paclitaxel; Thymidine phosphorylase

Indexed keywords

CHLORPHENIRAMINE; DEXAMETHASONE; DOXIFLURIDINE; FAMOTIDINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG POTENTIATION; FATIGUE; FEMALE; FEVER; HEADACHE; HISTOLOGY; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FLOXURIDINE; HEMATOPOIESIS; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; STOMACH NEOPLASMS; VOMITING;

EID: 20244387446     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995.
2. Watanabe S, Tanaka T, Takeuchi T, Takabayashi H and Hirayama Y: Advanced gastric cancer with liver metastases successfully treated with S-1. Int J Clin Oncol 7: 326-329, 2002.
3. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y and Hyodo I: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17: 319-323, 1999.
4. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W and Heldin C H: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338: 557-562, 1989.
5. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M and Yamada Y: Angiogenic factor. Nature 356: 668, 1992.
6. Sumizawa T, Furukawa T, Haraguchi M, Yoshimura A, Takeyasu A, Ishizawa M, Yamada Y and Akiyama S: Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J Biochem (Tokyo) 114: 9-14, 1993.
7. Osaki M, Sakatani T, Okamoto E, Goto E, Adachi H and Ito H: Thymidine phosphorylase expression results in a decrease in apoptosis and increase in intratumoral microvessel density in human gastric carcinomas. Virchows Arch 437: 31-36, 2000.
8. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998.
9. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T and Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 19: 1407-1411, 1996.
10. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa YSCK, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y and Manabe T: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17: 33-38, 2000.
11. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993.
12. Glimelius B, Hoffman K, Haglund U, Nyren O and Sjoden PO: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5: 189-190, 1994.
13. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R and Taguchi T: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21: 416-419, 1998.
14. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y and Taguchi T: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12: 1133-1137, 2001.
15. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R and Mansfield PF: Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4: 269-274, 1998.
16. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y and Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212, 2003.
17. Miwa, M, Cook A and Ishitsuka H: Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells. Chem Pharm Bull (Tokyo) 34: 4225-4232, 1986.
18. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998.
19. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H and Tanaka Y: Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83: 127-134, 1999.
20. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E and Diaz-Rubio E: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091, 2004.
21. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y and Ishitsuka H: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5: 2948-2953, 1999.
22. Yoshimoto M, Tada K, Tokudome N, Kutomi G, Tanabe M, Goto T, Nishimura S, Makita M and Kasumi F: The potential for oral combination chemotherapy of 5′-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer. Br J Cancer 89: 1627-1632, 2003.
23. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G and Bhalla K: High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8: 1960-1969, 1994.
24. Haldar S, Jena N and Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
25. Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
26. Fujimoto-Ouchi K, Tanaka Y and Tominaga T: Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5- fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 7: 1079-1086, 2001.
27. Hidaka S, Hyodo I, Moriwaki T, Nishina T and Nasu J: Paclitaxel/ doxifluridine as second-line treatment in patients with advanced gastric cancer. Meeting Proceedings of the Japanese Society of Gastric Cancer. The 76th Annual Meeting of the Japanese Society of Gastric Cancer, Abstract No. PO-301, 2004.
28. Yoshino S, Oka M, Hazama S, Hamano K, Hayashi H, Hasegawa H, Yamamoto T and Katoh T: A combination Phase I study of weekly paclitaxel and 5′-DFUR in patients with unresectable or recurrent gastric cancer in an outpatient setting. Meeting Proceedings of the American Society of Clinical Oncology (ASCO). The 40th Annual Meeting of the American Society of Clinical Oncology, Abstract No. 4228, 2004.